| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2021 | ELYSIUM THERAPEUTICS, INC. | 1201 E MARKET ST | AKRON | OH | 44305-4062 | SUMMIT | USA | R01DA046102 | Novel opioids that protect against oral overdose and disrupt the progression to misuse, abuse, and addiction | 000 | 3 | NIH | 11/9/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = -$3,370 ) |
| | 2023 | 2018 | ELYSIUM THERAPEUTICS, INC. | 1201 E MARKET ST | AKRON | OH | 44305-4062 | SUMMIT | USA | R43DA046302 | Novel Opioid Prodrugs with Oral Overdose Protection: Minimizing Cost-of-Goods | 000 | 1 | NIH | 10/17/2022 | -$3,370 |
|
| Issue Date FY: 2022 ( Subtotal = -$148,145 ) |
| | 2022 | 2019 | ELYSIUM THERAPEUTICS, INC. | 1201 E MARKET ST UNIT 604 | AKRON | OH | 44305-4062 | SUMMIT | USA | R44DA037908 | Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids | 000 | 6 | NIH | 5/23/2022 | -$151,553 |
| | 2022 | 2018 | ELYSIUM THERAPEUTICS, INC. | 1201 E MARKET ST UNIT 604 | AKRON | OH | 44305-4062 | SUMMIT | USA | R43DA046302 | Novel Opioid Prodrugs with Oral Overdose Protection: Minimizing Cost-of-Goods | 000 | 1 | NIH | 9/26/2022 | $3,407 |
|
| Issue Date FY: 2021 ( Subtotal = $452,530 ) |
| | 2021 | 2021 | ELYSIUM THERAPEUTICS, INC. | 1201 E MARKET ST UNIT 604 | AKRON | OH | 44305-4062 | SUMMIT | USA | R01DA046102 | Novel opioids that protect against oral overdose and disrupt the progression to misuse, abuse, and addiction | 000 | 3 | NIH | 2/8/2021 | $452,530 |
|
| Issue Date FY: 2020 ( Subtotal = $2,677,544 ) |
| | 2020 | 2020 | ELYSIUM THERAPEUTICS, INC | 64 EDGEGATE CT | DANVILLE | CA | 94506-1331 | CONTRA COSTA | USA | R01DA046102 | Novel opioids that protect against oral overdose and disrupt the progression to misuse, abuse, and addiction | 000 | 2 | NIH | 12/20/2019 | $2,409,790 |
| | 2020 | 2020 | ELYSIUM THERAPEUTICS, INC. | 64 EDGEGATE CT | DANVILLE | CA | 94506-1331 | CONTRA COSTA | USA | R01DA046102 | Novel opioids that protect against oral overdose and disrupt the progression to misuse, abuse, and addiction | 001 | 2 | NIH | 2/13/2020 | $267,754 |
|
| Issue Date FY: 2019 ( Subtotal = $986,127 ) |
| | 2019 | 2019 | ELYSIUM THERAPEUTICS, INC | 64 EDGEGATE CT | DANVILLE | CA | 94506-1331 | CONTRA COSTA | USA | R44DA037908 | Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids | 000 | 6 | NIH | 7/25/2019 | $990,284 |
| | 2019 | 2018 | ELYSIUM THERAPEUTICS, INC | 64 EDGEGATE CT | DANVILLE | CA | 94506-1331 | CONTRA COSTA | USA | R01DA046102 | Novel opioids that protect against oral overdose and disrupt the progression to misuse, abuse, and addiction | 000 | 1 | NIH | 4/19/2019 | $0 |
| | 2019 | 2018 | ELYSIUM THERAPEUTICS, INC | 64 EDGEGATE CT | DANVILLE | CA | 94506-1331 | CONTRA COSTA | USA | R43DA046302 | Novel Opioid Prodrugs with Oral Overdose Protection: Minimizing Cost-of-Goods | 000 | 1 | NIH | 7/19/2019 | -$4,157 |
|
| Issue Date FY: 2018 ( Subtotal = $4,104,716 ) |
| | 2018 | 2018 | ELYSIUM THERAPEUTICS, INC | 64 EDGEGATE CT | DANVILLE | CA | 94506-1331 | CONTRA COSTA | USA | R01DA046102 | Novel opioids that protect against oral overdose and disrupt the progression to misuse, abuse, and addiction | 000 | 1 | NIH | 6/7/2018 | $2,841,799 |
| | 2018 | 2018 | ELYSIUM THERAPEUTICS, INC | 64 EDGEGATE CT | DANVILLE | CA | 94506-1331 | CONTRA COSTA | USA | R43DA046302 | Novel Opioid Prodrugs with Oral Overdose Protection: Minimizing Cost-of-Goods | 000 | 1 | NIH | 2/22/2018 | $224,826 |
| | 2018 | 2018 | ELYSIUM THERAPEUTICS, INC | 64 EDGEGATE CT | DANVILLE | CA | 94506-1331 | CONTRA COSTA | USA | R43DA046302 | Novel Opioid Prodrugs with Oral Overdose Protection: Minimizing Cost-of-Goods | 001 | 1 | NIH | 6/11/2018 | $50,000 |
| | 2018 | 2018 | ELYSIUM THERAPEUTICS, INC | 64 EDGEGATE CT | DANVILLE | CA | 94506-1331 | CONTRA COSTA | USA | R44DA037908 | Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids | 002 | 5 | NIH | 7/11/2018 | $985,349 |
| | 2018 | 2017 | ELYSIUM THERAPEUTICS, INC | 64 EDGEGATE CT | DANVILLE | CA | 94506-1331 | CONTRA COSTA | USA | R44DA037908 | Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids | 001 | 4 | NIH | 1/9/2018 | $101,224 |
| | 2018 | 2016 | ELYSIUM THERAPEUTICS, INC | 64 EDGEGATE CT | DANVILLE | CA | 94506-1331 | CONTRA COSTA | USA | R44DA037908 | Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids | 000 | 3 | NIH | 1/9/2018 | -$101,224 |
| | 2018 | 2015 | ELYSIUM THERAPEUTICS, INC | 64 EDGEGATE CT | DANVILLE | CA | 94506-1331 | CONTRA COSTA | USA | R44DA037900 | Bio-Activated Opioid Drugs with Unprecedented Oral and Non-Oral Abuse-Resistance | 001 | 2 | NIH | 7/12/2018 | $0 |
| | 2018 | 2014 | ELYSIUM THERAPEUTICS, INC | 64 EDGEGATE CT | DANVILLE | CA | 94506-1331 | CONTRA COSTA | USA | R44DA037900 | Bio-Activated Opioid Drugs with Unprecedented Oral and Non-Oral Abuse-Resistance | 000 | 1 | NIH | 2/1/2018 | $2,742 |
|
| Issue Date FY: 2017 ( Subtotal = $986,904 ) |
| | 2017 | 2017 | ELYSIUM THERAPEUTICS, INC | 111 DEERWOOD RD STE 385 | SAN RAMON | CA | 94583-1777 | CONTRA COSTA | USA | R44DA037908 | Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids | 000 | 4 | NIH | 4/17/2017 | $986,904 |
| | 2017 | 2015 | ELYSIUM THERAPEUTICS, INC | 111 DEERWOOD RD STE 385 | SAN RAMON | CA | 94583-1777 | CONTRA COSTA | USA | R44DA037900 | Bio-Activated Opioid Drugs with Unprecedented Oral and Non-Oral Abuse-Resistance | 000 | 2 | NIH | 1/7/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $355,366 ) |
| | 2016 | 2016 | ELYSIUM THERAPEUTICS, INC | 9000 CROW CANYON RD STE S-243 | DANVILLE | CA | 94506 | CONTRA COSTA | USA | R44DA037908 | Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids | 000 | 3 | NIH | 4/21/2016 | $355,366 |
|
| Issue Date FY: 2015 ( Subtotal = $2,692,102 ) |
| | 2015 | 2015 | ELYSIUM THERAPEUTICS, INC | 9000 CROW CANYON RD STE S-243 | DANVILLE | CA | 94506 | CONTRA COSTA | USA | R44DA037900 | Bio-Activated Opioid Drugs with Unprecedented Oral and Non-Oral Abuse-Resistance | 000 | 2 | NIH | 2/27/2015 | $1,541,693 |
| | 2015 | 2015 | ELYSIUM THERAPEUTICS, INC | 9000 CROW CANYON RD STE S-243 | DANVILLE | CA | 94506 | CONTRA COSTA | USA | R44DA037908 | Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids | 001 | 2 | NIH | 6/10/2015 | $5,000 |
| | 2015 | 2015 | ELYSIUM THERAPEUTICS, INC | 9000 CROW CANYON RD STE S-243 | DANVILLE | CA | 94506 | CONTRA COSTA | USA | R44DA037908 | Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids | 000 | 2 | NIH | 4/22/2015 | $1,145,409 |
|
| Issue Date FY: 2014 ( Subtotal = $442,263 ) |
| | 2014 | 2014 | ELYSIUM THERAPEUTICS, INC | 9000 CROW CANYON RD STE S-243 | DANVILLE | CA | 94506 | CONTRA COSTA | USA | R44DA037900 | Bio-Activated Opioid Drugs with Unprecedented Oral and Non-Oral Abuse-Resistance | 000 | 1 | NIH | 8/8/2014 | $217,526 |
| | 2014 | 2014 | ELYSIUM THERAPEUTICS, INC | 9000 CROW CANYON RD STE S-243 | DANVILLE | CA | 94506 | CONTRA COSTA | USA | R44DA037908 | Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids | 000 | 1 | NIH | 9/3/2014 | $224,737 |
|
|
